GlaxoSmithKline
NEWS
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
Adaptimmune reported it saw three partial responses in three of the four myxoid/ round cell liposarcoma (MRCLS) patients the company dosed with its NY-ESO SPEAR T-cells.
Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion.
Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.
Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Bexsero is the first vaccine in the world to receive the designation twice.
Companies including Sanofi, J&J, Nestle have dropped out.
JOBS
IN THE PRESS